Overview

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Status:
Not yet recruiting
Trial end date:
2025-02-15
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, single-arm, phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of mitoxantrone hydrochloride liposome injection in subjects with acute myeloid leukemia (AML).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Mitoxantrone